The FDA decision on Myovant Sciences Ltd.’s (MYOV) Relugolix, proposed for the treatment of men with advanced prostate cancer, is slated for December 20.Relugolix is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist that reduces production of testicular testosterone, a hormone known to stimulate the growth of prostate cancer, and ovarian estradiol, a hormone known to stimulate the growth of uterine fibroids and endometriosis.In a phase III clinical trial, 96.7% of men treated with Relugolix achieved sustained testosterone suppression to castrate levels (less than 50 ng/dL) through 48 weeks compared to 88.8% of men treated with approved prostate cancer medication Leuprolide acetate, sold under the brand name Lupron, among others. If approved for the indication of prostate cancer, Relugolix will compete with AbbVie’s Lupron and AstraZeneca’s Zoladex.Relugolix is also under review for the treatment of women with heavy menstrual bleeding associated with uterine fibroids, with a decision anticipated on June 1, 2021.If all goes well as planned, Relugolix is estimated to achieve sales of $200 million by 2025, according to some analysts.MYOV closed Friday’s (Nov.27, 2020) trading at $23.53, up 7.69%.